Bristol-Myers Squibb (United Kingdom)

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III–IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of a...